{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:49:02Z","timestamp":1776919742507,"version":"3.51.2"},"reference-count":30,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,7,7]]},"abstract":"<jats:p>We describe three cases of patients with advanced adenocarcinoma of the lung and epidermal growth factor receptor (EGFR) mutation treated with erlotinib 25\u2005mg\/day and 25\u2005mg every second day, being equal to one-sixth and one-twelfth of the recommended dose. The mean age of our patients was above 70 with a WHO performance status 1 before and during the treatment. The reasons for erlotinib dose reduction were rash, diarrhoea and fatigue. The decision was a result of lack of other treatment options and radiological response on standard doses. We did not observe any liver enzyme abnormalities. However, the post-treatment creatinine increased significantly. As of February 2014, our patients are still on treatment with tolerable side effects and improved quality of life. These findings indicate that some patients responding to erlotinib with noxious side effects could have clinical benefit in doses much lower than recommended.<\/jats:p>","DOI":"10.1136\/bcr-2014-204809","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T13:59:22Z","timestamp":1406123962000},"page":"bcr2014204809","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation"],"prefix":"10.1136","volume":"2014","author":[{"given":"Weronika Maria","family":"Szejniuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluf Dimitri","family":"R\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Version 2.2014. Non-Small Cell Lung Cancer. 2014:30. http:\/\/www.nccn.org ."},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds226"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.08.003"},{"issue":"(Suppl 5)","key":"2025042706104705000_2014.jul23_1.bcr2014204809.5","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper","year":"2013","journal-title":"J Thorac Dis"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.03.001"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.8","doi-asserted-by":"crossref","unstructured":"Chen X Liu Y R\u00f8e OD . Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS ONE 2013;8. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23555654","DOI":"10.1371\/journal.pone.0059314"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-7-461"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.10","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1455"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.12","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32833034e1"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.15","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181bbb2b9"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.16","doi-asserted-by":"publisher","DOI":"10.1159\/000345039"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0b013e3181dd1386","article-title":"Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations","volume":"5","author":"Yeo","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.18","first-page":"2800","article-title":"EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence","volume":"6","author":"Szumera-cie\u0107kiewicz","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.19","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2013.04.005"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.22","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31827e2145"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0088"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.25","unstructured":"OSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US I. 2013. Tarceva Prescribing Information. NY; 2013:1\u201318. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021743s018lbl.pdf ."},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0109-x"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6210"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JTO.0b013e31802bffb0","article-title":"Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure","volume":"2","author":"Gridelli","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.29","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-201296"},{"key":"2025042706104705000_2014.jul23_1.bcr2014204809.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.06.009"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-204809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:10:57Z","timestamp":1745759457000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-204809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":30,"alternative-id":["10.1136\/bcr-2014-204809"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-204809","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}